Tower Research Capital (TRC)’s Kailera Therapeutics KLRA Stock Holding History
Bought
Maintained
Sold
Other funds holding KLRA
Tower Research Capital (TRC)'s KLRA Position: Q3 2026 in Review
Tower Research Capital (TRC) increased its Kailera Therapeutics (KLRA) stake by 14% in Q3 2026, buying an estimated $7.66K and bringing the position to 3,742 shares worth $42.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3317.
Tower Research Capital (TRC) first reported a position in KLRA in Q2 2026 and has held it in 2 quarters since. The position peaked at $72.5K in Q2 2026. 132 funds tracked by Wall St. Rank hold KLRA as of Q3 2026.
- Tower Research Capital (TRC) held 3,742 shares of Kailera Therapeutics worth $42.7K as of Q3 2026.
- Tower Research Capital (TRC) bought 453 Kailera Therapeutics shares in Q3 2026, an estimated $7.66K.
- Kailera Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q3 2026, its #3317 holding.
- Tower Research Capital (TRC) first reported a position in Kailera Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Tower Research Capital (TRC)'s Kailera Therapeutics position peaked at $72.5K in Q2 2026.
- 132 funds tracked by Wall St. Rank held Kailera Therapeutics as of Q3 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q3 2026, filed 16 Nov 2026.